CRISPR Gene Therapies Move From Edited Cells Toward Direct Genome Editing Inside the Body

CRISPR gene editing is moving into a new phase of medicine, from modifying a patient’s cells outside the body to testing whether genetic changes can be made directly inside human tissues. The FDA-approved therapy Casgevy has already established CRISPR as a clinical treatment for sickle cell disease and transfusion-dependent beta-thalassemia, while experimental in-vivo programs have demonstrated that genome editing can be delivered directly to tissues such as the retina. Cystic fibrosis remains an important target for future CRISPR therapies, but clinical in-vivo editing for the disease has not yet reached the same stage.

From Laboratory Gene Editing to an Approved Medicine

For years, CRISPR was primarily associated with laboratory experiments in which scientists altered DNA in cells outside the body. The development of Casgevy (exagamglogene autotemcel) changed that picture.

In December 2023, the U.S. Food and Drug Administration approved Casgevy for people aged 12 and older with sickle cell disease and recurrent vaso-occlusive crises. In January 2024, the FDA also approved it for transfusion-dependent beta-thalassemia. In July 2026, the agency expanded the treatment to patients as young as 2 years old for both conditions.

Casgevy is a CRISPR/Cas9-based cell therapy, but it is not an in-vivo treatment. Doctors collect blood-forming stem cells from the patient, send them through a manufacturing process where CRISPR edits their DNA, and then return the modified cells to the patient following intensive conditioning treatment.

The editing is designed to disrupt a regulatory region associated with BCL11A, allowing the treated cells to produce more fetal hemoglobin. Higher fetal hemoglobin can reduce the tendency of red blood cells to sickle and can reduce transfusion dependence in beta-thalassemia.

That distinction matters because the next challenge is considerably more complicated: Can the editing machinery be delivered to the right cells while they remain inside the human body?

What “In Vivo” CRISPR Actually Means

In-vivo gene editing means that the molecular machinery required to alter DNA is delivered directly into a patient’s body rather than removing cells, editing them in a laboratory and returning them.

The approach can potentially simplify treatment for diseases where the relevant cells are difficult or impractical to remove and manipulate outside the body.

But it also creates a demanding delivery problem.

The CRISPR system has to reach the correct tissue, enter the appropriate cells, identify the intended genetic sequence and make the desired change without producing harmful unintended edits elsewhere.

The delivery method therefore becomes almost as important as the editing technology itself.

The Eye Became an Early Testing Ground

One of the clearest demonstrations of in-vivo CRISPR in humans has come from inherited retinal disease.

In 2020, the first patient was treated in the BRILLIANCE clinical trial of EDIT-101, an experimental CRISPR/Cas9 therapy developed for Leber congenital amaurosis type 10 (LCA10), a rare inherited retinal disorder associated with mutations in the CEP290 gene. The treatment was delivered by a subretinal injection designed to bring the editing machinery directly to retinal cells.

The eye offers an unusual environment for gene-editing research because treatments can be delivered locally to a relatively contained tissue.

Results from the Phase 1/2 study provided early evidence that editing inside the human retina was biologically possible. In a peer-reviewed report involving 14 treated participants, six showed meaningful improvement in cone-mediated vision, while nine showed meaningful improvement in at least one of several measured visual outcomes.

Those findings do not establish a broadly available treatment for inherited blindness. EDIT-101 remains an investigational therapy, and the small study was designed primarily to examine safety, tolerability and early evidence of biological activity.

Nevertheless, the trial demonstrated something important for the field: CRISPR editing does not necessarily have to happen outside the body.

The Next Challenge Is Reaching the Right Tissue

The retina is only one possible destination.

Researchers are developing in-vivo approaches for tissues including the liver, where lipid nanoparticles can deliver CRISPR components to cells after systemic administration. Several experimental programs have already entered human trials for diseases such as transthyretin amyloidosis and hereditary angioedema.

This represents a broader shift in gene-editing research.

Instead of thinking of CRISPR as a single treatment technology, scientists are increasingly treating it as a platform whose success depends on three interconnected components: the genetic target, the molecular editor and the delivery system.

A powerful editor is of limited value if it cannot reach the correct cells.

Why Cystic Fibrosis Is a Much Harder Test

Cystic fibrosis illustrates why the transition to in-vivo editing is difficult.

The disease is caused by mutations in the CFTR gene, which affects the movement of salt and water across cell membranes. The lungs are a major site of disease, but delivering gene-editing machinery throughout the relevant airway cell populations presents major biological and technical challenges.

Scientists have already demonstrated CRISPR-based correction of CFTR mutations in patient-derived cells, organoids and animal models. More recent research has also explored lipid nanoparticles capable of delivering base-editing machinery to lung stem cells in mice, producing substantial genetic correction in experimental models.

But these results should not be confused with a human clinical therapy.

As of 2026, the evidence does not support describing in-vivo CRISPR editing for cystic fibrosis as an established U.S. clinical-trial program comparable to the inherited-blindness work. Reviews of the field continue to identify delivery to the airway and durable correction of the appropriate stem-cell populations as major obstacles.

That makes cystic fibrosis an important example of where the science may be heading rather than evidence that the destination has already been reached.

Safety Remains a Central Question

Editing DNA inside the body introduces risks that researchers have to monitor carefully.

One concern is off-target editing, in which the genome-editing machinery alters a DNA sequence other than the intended target. Other considerations include immune responses, delivery-related toxicity, the persistence of editing machinery and what happens to edited cells over many years.

The FDA’s current Casgevy information specifically includes warnings related to off-target genome editing and requires long-term monitoring.

In-vivo therapies add another layer of complexity because the editing components themselves are administered directly to the patient.

Scientists therefore need to establish not only whether an edit occurs, but also where it occurs, how efficiently it occurs and whether the resulting biological changes remain beneficial over time.

A Different Model for Genetic Medicine

The significance of the current CRISPR transition is not that every inherited disease is suddenly treatable.

Instead, the field is gradually demonstrating that genetic medicine can operate at several levels.

Casgevy shows that CRISPR-edited cells can become an approved therapy when they can be collected, modified and returned to the patient. EDIT-101 demonstrated that experimental CRISPR machinery can also be delivered directly to human tissue. Other in-vivo programs are testing whether the same fundamental concept can be extended to organs reached through systemic delivery.

The long-term objective is more ambitious: develop editing systems that can reach the correct cells inside the body, make precise genetic changes and do so with a safety profile suitable for routine medical use.

That future is not here yet.

But the progression from laboratory editing, to ex-vivo clinical therapies, to direct editing inside human tissues marks a significant change in what genetic medicine can realistically attempt.

The Road Ahead for CRISPR

The next generation of CRISPR therapies will be judged less by how precisely scientists can edit DNA in a laboratory and more by whether they can safely deliver that precision to the right cells in living patients.

Inherited retinal disease has provided one early demonstration. Blood disorders have already produced an FDA-approved CRISPR therapy. Diseases affecting organs such as the liver are now being explored with systemic in-vivo editing.

For conditions such as cystic fibrosis, however, the central scientific challenge remains unsolved: reaching and durably correcting the right airway cells at sufficient scale.

The story of CRISPR is therefore moving beyond the question of whether DNA can be edited.

The harder question is becoming where, how and safely enough to make that edit matter inside a human body.

Most Searched 5 FAQs

1. What is CRISPR gene therapy?

CRISPR gene therapy uses genome-editing technology to make targeted changes to DNA. Depending on the treatment, cells can be edited outside the body and returned to the patient, or the editing machinery can be delivered directly into the body.

2. Is Casgevy an in-vivo CRISPR therapy?

No. Casgevy uses CRISPR/Cas9 to edit a patient’s blood-forming stem cells outside the body before the modified cells are infused back into the patient.

3. Has CRISPR been used directly inside the human body?

Yes. Experimental in-vivo CRISPR therapies have been administered to humans. EDIT-101, for example, was delivered directly to the retina in a clinical trial for LCA10.

4. Is there a CRISPR treatment for cystic fibrosis?

No approved CRISPR treatment for cystic fibrosis currently exists. Researchers have demonstrated promising gene-editing approaches in cells and animal models, but safely delivering and maintaining effective CFTR correction throughout the relevant airway cells remains a major challenge.

5. What is the biggest challenge for in-vivo CRISPR?

One of the biggest challenges is delivery: getting the gene-editing machinery into the correct cells while limiting unintended effects. Long-term safety, off-target editing and durability of the genetic change are also major considerations.